retatrutide phase 2 results obesity nejm 2023 🚨 is out: 24.2% mean weight loss and a quarter lost >30%! Women lost more weight than men. #ADA2023 was like drinking from a fire hose for emerging anti-obesity Triple hormone receptor agonist retatrutide

Refunds are not issued for subscription fees, but you may receive a credit in the event of shipping errors

Use in conjunction with any sensible diet and exercise program

The Phase 2 trials only report results while still on the medication

Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial

Inquire about their approach to managing excess skin versus fat removal and their revision rates for similar procedures

women of childbearing potential should discuss contraception with their prescriber before starting any weight-management medicine Without clinical supervision, monitoring of blood glucose, IGF-1 levels, lipid panels, and cardiovascular parameters would not be in place, significantly increasing the risk of undetected harm